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Comparison of different lots of endotoxin
and evaluation of in vivo potency over
time in the experimental human
endotoxemia model
Dorien Kiers1,2,#, Guus P. Leijte1,2,# , Jelle Gerretsen1,2,
Jelle Zwaag1,2, Matthijs Kox1,2 and Peter Pickkers1,2
Abstract
The experimental human endotoxemia model is used to study the systemic inflammatory response in vivo. The previ-
ously used lot of endotoxin, which was used for over a decade, is no longer approved for human use and a new Good
Manufacturing Practices-grade batch has become available. We compared the inflammatory response induced by either
bolus or continuous administration of either the previously used lot #1188844 or new lots of endotoxin (#94332B1 and
#94332B4). Compared with lot #1188844, bolus administration of lot #94332B1 induced a more pronounced systemic
inflammatory response including higher plasma levels of pro-inflammatory cytokines and more pronounced clinical signs
of inflammation. In contrast, continuous infusion of lot #94332B4 resulted in a slightly less pronounced inflammatory
response compared with lot #1188844. Furthermore, we evaluated whether lot #1188844 displayed in vivo potency loss
by reviewing inflammatory parameters obtained from 17 endotoxemia studies performed in our centre between 2007
and 2016. Despite inter-study variability in endotoxemia-induced effects on temperature, heart rate, symptoms, and
leukocyte counts, the magnitude of these effects did not decrease over time. In conclusion, although all lots of endotoxin
induce a pronounced inflammatory response, the magnitude differs between lots. We observed no potency loss of
endotoxin over time.
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Introduction
A dysregulated systemic inflammatory response plays a
role in a plethora of pathological conditions, such as
sepsis,1 trauma,2 burns,3 and major surgery.4 An over-
zealous response may harm the patient by inducing
tissue damage. However, a suppressed inflammatory
response can be equally detrimental, as it compromises
the host’s ability to combat infections. The experimental
human endotoxemia model has contributed consider-
ably to our understanding of the systemic inflammatory
response. In this model, intravenous administration of
bacterial endotoxin, mostly Escherichia coli derived, to
healthy volunteers results in a transient systemic inflam-
matory response.5,6 This response is characterized by
increased cytokine mRNA expression and plasma
levels, haemodynamic alterations, fever, and flu-like
symptoms.7–10 Compared with the uncertainties
regarding the cause, time of onset and extent of inflam-
mation,11 and large inter-individual differences in age,
comorbidities and medication use, for example in
patients with sepsis, the experimental human endotox-
emia is considered a standardized, controlled and safe
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model of systemic inflammation.5 Over time, different
lots of E. coli endotoxin have been in use. The EC-5 lot,
derived from non-Good Manufacturing Practices
(GMP) bulk material, was vialled in 1976 and distribut-
ed by the Food and Drug Administration (FDA), but
use of this lot was ceased in the late 1990s, as it did not
meet regulatory standards. In 1997 and 2006, two new
lots (#67801 and #1188844, respectively) derived from
the same non-GMP bulk material used for EC-5, were
vialled under GMP conditions by the National
Institutes of Health (NIH). These lots were named
Clinical Center Reference Endotoxin (CCRE). Back
then, researchers were under the impression that the
EC-5 lot had lost its potency to elicit a systemic inflam-
matory response,12 which was confirmed in a head-to-
head comparison of EC-5 with CCRE.13 From 1997 to
2016, the CCRE lots were provided to researchers by the
Clinical Center Endotoxin Repository of the NIH, who
also coordinated potency and sterility testing. Recently,
the FDA required the use of full GMP pharmaceutical-
grade endotoxin. Therefore, use of the CCRE lot was no
longer permitted and production of a novel GMP-grade
CCRE batch was commissioned by the NIH, and pro-
duced by List Biologicals Laboratories Inc. (Campbell
CA, USA).
For the comparison of data obtained in different
experimental human endotoxemia studies, it is impor-
tant to know whether the systemic inflammatory
response induced by lot #1188844 and the new GMP-
grade lots are comparable. In addition, although it was
previously concluded that the EC-5 lot lost potency
over time, the question remains whether this also
applies to the #1188844 lot, which may be relevant
for new batches and lots.
Herein, we performed a head-to-head comparison of
the systemic inflammatory response induced by different
lots of endotoxin using bolus as well as continuous
administration. First, we compared the response to
bolus administration of the #1188844 lot and the novel
#94332B1 lot. Second, we compared the response to con-
tinuous infusion of the #1188844 lot and another new
lot, named #94332B4. We assessed plasma cytokine/che-
mokine levels, haemodynamic alterations, symptoms,
and changes in leukocyte counts. Furthermore, to
assess potential potency loss of the #1188844 lot over
time, we reviewed clinical parameters of systemic inflam-
mation obtained in 17 endotoxemia studies performed at
our department between 2007 and 2016.
Material and methods
Study design
For head-to-head comparison of different lots of endo-
toxin, we compared clinical parameters of systemic
inflammation and cytokine/chemokine data obtained
from two studies in which subjects received a bolus
administration of 2 ng/kg endotoxin from either the
lot #1188844 (vialled in 2006) or lot #94332B1 (new
GMP-grade lot), and from two studies in which bolus
administration of 1 ng/kg of endotoxin was followed
by continuous infusion of endotoxin at a dose of
1 ng/kg/h for 3 h using either lot #1188844 or lot
#94332B4 (another new GMP-grade lot). To assess
potential potency loss of lot #1188844 over time, we
compared clinical parameters of systemic inflammation
obtained from subjects randomized to the control
groups (no intervention besides administration of
endotoxin) of 17 human endotoxemia studies per-
formed at the department of Intensive Care Medicine
of the Radboud university medical center using the
bolus model (administration of 2 ng/kg endotoxin, lot
#1188844) from 2007 to 2016. A list of included studies
is provided in Table 1. To compare these responses
with those observed after bolus administration of a
new GMP-grade batch, we used data obtained in the
above described study employing bolus administration
of 2 ng/kg #94332B1.
Apart from the use of different batches of endotox-
in, the study procedures were identical and in accor-
dance with the declaration of Helsinki, including the
latest revisions. All studies were approved by the
local ethics committee (CMO Arnhem-Nijmegen),
and registration numbers are listed in Table 1. Data
of most studies described in this work have been pub-
lished previously (references provided in Table 1).
In all studies, eligible subjects were healthy, non-
smoking males aged 18–35 yr. Subjects were included
after providing written informed consent and when
declared eligible based on a full medical history, a
normal physical examination, electrocardiography,
and routine laboratory values. Exclusion criteria
were pre-existent disease, drug use, and febrile illness
in the past 4 wk. The experiments were performed in
accordance to our standardized protocol described in
detail elsewhere.6 In short, subjects refrained from caf-
feine and alcohol for 24 h and from food and drinks
for 12 h before the experiment. Continuous blood
pressure monitoring and blood withdrawal were facil-
itated by placement of an arterial cannula. Endotoxin
and intravenous hydration were administered through
a venous cannula. Heart rate was registered with a
three-lead electrocardiogram, and all haemodynamic
data were recorded. Every 30 min, temperature was
measured using a tympanic thermometer and flu-like
symptoms (headache, nausea, shivering, muscle and
back pain) were scored on a six-point Likert scale
(0¼no symptoms, 5¼worst ever experienced) with
addition of 3 points for vomiting, resulting in a
total symptom score ranging from 0–28.
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Furthermore, subjects were pre-hydrated by infusion
of 1.5 l Glc 2.5%/NaCl 0.45% during the 1-h-period
prior to start of endotoxin administration, because
this decreases the chances of a vasovagal reaction
during endotoxemia.14 Hereafter, hydration was con-
tinued with 150 ml/h for 8 h.
Endotoxin
All endotoxin lots were derived from an E. coli Type
O113:H10:K-negative strain of bacteria. Endotoxin
was stored at the investigational site in a dedicated
fridge at 2–8C, and reconstituted prior to administra-
tion, both according to the manufacturer’s instructions.
The temperature of the fridge was constantly moni-
tored and logged using an automated system. Lot
#1188844 was derived from bulk material produced
by the National Institute of Allergy and Infectious
Diseases and FDA in 1967 and vialled in 2006 under
GMP conditions by the Pharmaceutical Development
Section of the NIH (Bethesda, MD, USA). The lots
#94332B1 and #94332B4 were both derived from the
same new GMP-grade bulk material and vialled under
GMP conditions by List Biological Laboratories,
Inc (Campbell, California, USA). This GMP-grade
endotoxin has previously shown to be safe for admin-
istration in humans.15
Cytokine and chemokine analysis
EDRTA-anticoagulated blood was collected at various
time points up to 8 h after start of endotoxin adminis-
tration. After centrifugation (2000 g, 4C, 10 min),
plasma was stored at –80C until further analysis.
Concentrations of TNF-a, IL-6, IL-8, IL-10,
Monocyte Chemoattractant Protein (MCP)-1 and
Monocyte Inflammatory Protein (MIP)-1b were mea-
sured using a simultaneous Luminex assay (Milliplex,
Merck Millipore, Billerica, MA, USA). To enable
head-to-head comparison of studies using different
endotoxin lots, cytokine/chemokine analysis was per-
formed batchwise (in one run). For all measured medi-
ators, the lower detection limit was 3.2 pg/ml.
Leukocyte counts
Analysis of leukocyte (subset) counts was performed
using standardized routine methods at the
Laboratory of Clinical Chemistry of the Radboud uni-
versity medical center.
In vitro endotoxin potency
All endotoxin vials described in this study contained
1 mg of endotoxin, which is claimed to correspond to
a potency of 10.000 endotoxin units (EU) per vial.
Table 1. Experimental human endotoxemia studies included for analyses.
yr n Registration number
Mode of
administration Lot
23 2007 10 NL17473.091.07 bolus #1188844
24 2007 7 NL20388.091.07 bolus #1188844
25 2008 10 NL24017.091.08 bolus #1188844
submitted 2009 10 NL27052.091.09 bolus #1188844
26 2009 10 NL29171.091.09 bolus #1188844
27 2009 6 NL27963.091.09 bolus #1188844
28 2009 10 NL30625.091.09 bolus #1188844
29 2011 6 NL36068.091.11 bolus #1188844
30 2011 12 NL38438.091.11 bolus #1188844
31 2012 12 NL42337.091.12 bolus #1188844
32 2013 10 NL43020.091.12 bolus #1188844
33 2013 10 NL44630.091.13 bolus #1188844
submitted 2015 12 NL49674.091.14 bolus #1188844
submitted 2015 10 NL53584.091.15 bolus* #1188844
35 2015 10 NL51923.091.14 continuous* #1188844
34 2016 15 NL54870.091.15 bolus #1188844
in preparation 2016 10 NL53411.091.15 bolus #1188844
submitted 2016 12 NL56686.091.16 bolus #1188844
in press 2016 20 NL57410.091.16 continuous* #94332B4
in preparation 2017 8 NL61136.091.17 bolus* #94332B1
Registration number represents registration at the Dutch national registry (toetsingonline.nl) for medical research involving human subjects. Lot
#1188844 was produced in 2006 and lots #94332B1 and #94332B4 in 2015. Bolus administration was performed at a dose of 2 ng/kg, continuous
administration was performed by infusion of 1 ng/kg, followed by 1 ng/kg/h for 3 h.
*studies included in the head-to-head comparison.
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In vitro potency measurements of lot #1188844 were
commissioned by the NIH to determine the actual
potency, and were performed on randomly selected
vials, by commercial entities with extensive experience
in the conduct of endotoxin assays. List Biologicals
performed in vitro potency measurements for the
#94332 batch. In vitro potency was quantified as EU/
vial using the Limulus amebocyte lysate (LAL) test.
This test is based upon a clotting reaction of amoebo-
cytes form the Limulus polyphemus with endotoxin, and
estimates the endotoxin content with an uncertainty
range of 50–200%.16
Statistical analysis
Distribution of data was tested for normality using the
Shapiro–Wilk test. Data are presented as mean with
SEM. Between-group differences over time were ana-
lysed using repeated measures two-way ANOVA
(group * time interaction term). Linear regression anal-
ysis was performed to assess changes over time in the
studies performed between 2007 and 2016 and coeffi-
cients of variation were calculated to assess inter-study
variation. Clinical parameters of systemic inflamma-
tion obtained from the study using bolus administra-
tion of lot #94332B1 were compared with values
obtained from all studies with lot #1188844 using
unpaired Student’s t-tests. Statistical analyses were per-
formed using Graphpad Prism version 5.03 (Graphpad
Software, San Diego, CA, USA). P-Values <0.05 were
considered statistically significant.
Results
Head-to-head comparison of the systemic
inflammatory response induced by different lots
of endotoxin
Demographic characteristics and safety. Demographic
characteristics of the subjects participating in the stud-
ies employing bolus and continuous endotoxin admin-
istration are listed in Tables 2a and 2b, respectively.
Apart from a higher body mass index (BMI), subjects
that received a bolus administration of lot #94332B1
were comparable to those that received the #1188844
lot. All subjects were well at time of discharge and no
serious adverse events occurred in any of the studies.
Plasma cytokine and chemokine levels. Bolus as well as con-
tinuous administration of endotoxin resulted in a pro-
found increase in plasma levels of TNF-a, IL-6, IL-8,
IL-10, MCP-1, MIP-1a, and MIP-1b (Figures 1 and 2).
In the bolus model, concentrations of the pro-
inflammatory mediators TNF-a, IL-6, IL-8, MCP-1,
MIP-1a, and MIP-1b were significantly higher in
response to administration of #94332B1 compared
with administration of lot #1188844 (Figure 1). There
were no differences in levels of the anti-inflammatory
cytokine IL-10. The cytokine/chemokine responses
induced by continuous infusion with either lot
#1188844 or #94332B4 were highly comparable for
IL-6, IL-8, MCP-1, MIP-1a, and MIP-1b, whereas
plasma concentrations of TNF-a and IL-10 were sig-
nificantly higher in subjects who received lot #1188844
(Figure 2).
Flu-like symptoms, temperature and haemodynamic changes.
Administration of endotoxin resulted in flu-like symp-
toms in all subjects, mainly consisting of headache,
shivering, muscle and back pain, occasionally nausea
and, incidentally, vomiting (Figures 3a and 4a). As
expected, systemic inflammation was characterized by
an increase in body temperature and heart rate, and a
decrease in mean arterial pressure (Figure 3b–d
and 4b–d). Bolus administration of lot #94332B1
resulted in an earlier onset of symptoms (Figure 3a),
with distinctly higher temperature and heart rate, and a
lower mean arterial pressure compared with adminis-
tration of lot #1188844 (Figure 3b–d). Continuous
infusion of lot #94332B4 resulted in a more gradual
development of symptoms compared with infusion of
the #1188844 lot, with lower symptom scores at 1.5 and
2 h after start of endotoxin infusion (Figure 4a).
Correspondingly, the increase in heart rate was more
pronounced in subjects that received lot #1188844,
accompanied by a slightly, but significantly, more
pronounced decrease in mean arterial pressure
Table 2. Demographic characteristics of subjects receiving (A)
bolus and (B) continuous administration of different lots
of endotoxin.
A
Bolus
Lot #1188844
n¼ 10
Lot #94332B1
n¼ 8 P-Value
Age [yr] 22.1 1.0 24.1 1.4 0.24
Height [cm] 183 4 184 1 0.96
Mass [kg] 73 2 86 1 <0.001
BMI [kg/m2] 21.8 0.6 25.5 0.4 <0.001
B
Continuous
Lot #1188844
n¼ 10
Lot #94332B4
n¼ 20
P-Value
Age [yr] 23.6 1.6 22.4 0.5 0.36
Height [cm] 182 2 182 1 0.77
Mass [kg] 77 4 82 2 0.23
BMI [kg/m2] 23.2 0.7 24.5 0.9 0.16
Data were obtained during screening visit and are presented as mean
 SEM. P-Values were calculated with unpaired Student’s t-tests.
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(Figure 4c, d). There was no significant difference in the
course of temperature between the groups (Figure 4b).
Haematological parameters. Bolus administration
resulted in a transient decrease in neutrophils, lympho-
cytes and monocytes, followed by a distinct neutro-
philia (Figure 5a–c). Compared with lot #1188844,
neutrophilia was more pronounced (Figure 5a),
there was a trend towards prolonged monocytopenia
(Figure 5b), and the initial decrease in lymphocyte
numbers (Figure 5c) was more marked after adminis-
tration of lot #94332B1. Continuous infusion of
both lots of endotoxin caused a transient mono- and
lymphocytopenia, followed by a neutrophilia and
monocytosis, without any differences between lots
(Figure 6a–c).
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Figure 1. Plasma cytokine/chemokine levels upon bolus administration of endotoxin of lot #1188844 (n¼ 10) and lot #94332B1
(n¼ 8). Plasma concentrations (pg/ml) of TNF-a, IL-6, IL-8, IL-10, MCP-1, MIP-1a, and MIP-1b are depicted over time. At t¼ 0
endotoxin was administered at a dose of 2 ng/kg. Data are expressed as mean SEM. Differences between groups were evaluated
using two-way ANOVA on log transformed data and interaction term (time group) P-values are displayed.
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Assessment of potential potency loss of lot
#1188844 over time
Between 2007 and 2016, 17 experimental human endo-
toxemia studies were performed at our centre using
bolus administration of 2 ng/kg of lot #1188844
(Table 1). Linear regression revealed no significant
changes over time in temperature, leukocyte count,
and symptom score (Figure 7a, 7c and 7d, respectively).
There was a slight, but significant, increase in peak
heart rate over the years (Figure 7b). Inter-study vari-
ability for the endotoxin-induced effects on heart rate
and leukocyte counts was relatively small (variation
coefficients of 4.9% and 10.2%, respectively), whereas
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40001000
600
400
200
0
800 3000
2000
1000
0
pg
/m
L
pg
/m
L
pg
/m
L
pg
/m
L
p=0.80
IL-6 #1188844
#94332B4
0 1 2 3 4 5 6 7 8
0 1 2 3 4 5 6 7 8
0 1 2 3 4 5 6 7 8 0 1 2 3 4 5 6 7 8
0 1 2 3 4 5 6 7 8
0 1 2 3 4 5 6 7 8
800 3000
2000
1000
0
600
400
200
500
400
300
200
100
6000
4000
2000
0
0
0
p=0.46 p=0.01
IL-8 IL-10
p=0.22 p=0.19
p=0.09
MIP-1α
MCP-1
4000
3000
2000
1000
0
MIP-1β
Time (h)
0 1 2 3 4 5 6 7 8
Time (h)
Figure 2. Plasma cytokine/chemokine levels upon continuous administration of endotoxin of lot #1188844 (n¼ 10) and lot
#94332B4 (n¼ 20). Plasma concentrations (pg/ml) of TNF-a, IL-6, IL-8, IL-10, MCP-1, MIP-1a, and MIP-1b are depicted over time. At
t¼ 0 endotoxin was administered at a dose of 1 ng/kg, followed by a continuous infusion of 1 ng/kg/h for 3 h, as indicated by the grey
bar. Data are expressed as mean SEM. Differences between groups were evaluated using two-way ANOVA on log transformed data
and interaction term (time group) P-values are displayed.
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#94332B1 (n¼ 8). Changes over time of (a) symptoms (arbitrary units), (b) temperature (C), (c) heart rate (beats per min [bpm]),
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inter-study variation in temperature changes (15.3%)
and peak symptom scores (24.7%) was more substan-
tial. Furthermore, the in vitro endotoxin potency was
highly variable over the years (30.4%) but did not sig-
nificantly decrease over time (Figure 7e).
To provide an additional assessment of the in vivo
potency of the new lot #94332B1 versus the previously
used #1188844 lot, we compared clinical parameters of
systemic inflammation induced by bolus administration
of #94332B1 (n¼ 8) with the aggregate mean of these
parameters obtained from the previous 17 studies using
bolus administration of #1188844 (n¼ 172). The max-
imum temperature increase was significantly higher
after administration of #94332B1 compared with lot
#1188844 (2.7 0.1 vs. 1.6 0.1ᵒC, respectively,
P¼ 0.0001, Figure 7a), as was the maximum heart
rate (104 3 vs. 94 1 beats per min, P< 0.0001,
Figure 7b). Peak leukocyte numbers (15.0 1.7 vs.
11.0 0.3 109/ml, P¼ 0.10, Figure 7c) and maximum
symptom scores (7.0 1 vs. 5.9 0.3, P¼ 0.31,
Figure 7d) were comparable between lots.
Discussion
In the present work, we compare the systemic inflam-
matory response induced by two lots derived from a
new GMP-grade batch of endotoxin with the response
induced by the previously used lot #1188844 in humans
in vivo. Compared with lot #1188844, bolus adminis-
tration of the new #94332B1 lot resulted in a more
pronounced inflammatory response, with higher levels
of pro-inflammatory cytokines and chemokines, an ear-
lier onset of symptoms, higher temperatures and heart
rate, and more profound neutrophilia. In contrast,
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Figure 5. Circulating neutrophil (a), monocyte (b), and lym-
phocyte (c) numbers upon bolus administration of endotoxin of
lot #1188844 (n¼ 10) and #94332B1 (n¼ 8). At t¼ 0 endotoxin
was administered at a bolus dose of 2 ng/kg. Data are expressed
as mean SEM. Differences between groups were evaluated
using two-way ANOVA and interaction term (time group) P-
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Figure 6. Circulating neutrophil (a), monocyte (b), and lym-
phocyte (c) numbers upon continuous administration of endo-
toxin of lot #1188844 (n¼ 10) and #94332B4 (n¼ 20). At t¼ 0
endotoxin was administered at a dose of 1 ng/kg, followed by a
continuous infusion of 1 ng/kg/h for 3 h, as indicated by the grey
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groups were evaluated using two-way ANOVA and interaction
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continuous infusion of another new lot (#94332B4)
resulted in a slightly less pronounced inflammatory
response compared with continuous infusion of
#1188844, with lower levels of TNF-a and IL-10 and
a more gradual onset of symptoms and increase in
heart rate, but no differences in other cytokines/chemo-
kines, temperature, or leukocyte numbers. In addition,
despite considerable inter-study variability especially in
flu-like symptoms and fever, no decline in endotoxin-
induced clinical parameters of systemic inflammation
were observed over a period of 10 yr in our centre,
indicating that the #1188844 lot did not lose potency.
A previous study compared the in vivo potency of
the EC-5 lot (which was used until 1999) with that
of the CCRE lot vialled in 1997 (#67801). Both of
these lots were derived from the same bulk material.
This head-to-head comparison, using bolus administra-
tion (4 ng/kg) in four subjects per group,13 showed that
administration of the older EC-5 lot resulted in lower
peak temperatures, leukocyte counts, cytokine
responses, cortisol production, and C-reactive protein
levels. Based on this, the authors concluded that endo-
toxin may lose its potency over the years. In the current
work, we have not only evaluated cytokine responses
and inflammatory parameters of lot #1188844 versus
two lots derived from novel GMP-grade bulk material,
but we also performed an over-time analysis of clinical
parameters of systemic inflammation induced by lot
#1188844 in a large group of subjects. These in vivo
data did not show a time-dependent decrease in effect
size. Although we observed a slight increase in peak
heart rate over the years, these changes were not related
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Figure 7. In vivo potency of endotoxin administration of lot #1188844 over time. Clinical parameters of systemic inflammation
induced by bolus administration of 2 ng/kg lot #1188844 in studies performed in our center from 2007 to 2016 (in black) and novel lot
#94332B1 in 2017 (in red) are depicted. Maximum temperature increase (D temperature) (a), peak heart rate (b), peak leukocytes (c),
and peak symptoms (d). In vitro potency as determined by LAL tests between 2007 and 2015 for lot #1188844, and for the #94332B1
lot in 2017 (e). Data are expressed as meanSEM. Linear regression analysis was performed, and the slopes (R) with 95% confidential
intervals and P-values are reported.
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to differences in body temperature, and despite being
statistically significant, the rather small increase likely
has limited relevance.
The in vitro quantification of endotoxin potency is
notoriously difficult, and various methods have been
described over the years.17 The LAL assay is the
most well-known method, and this was also employed
for the in vitro potency data reported in the current
work.16 In this assay, specimens and controls are dilut-
ed serially and these dilutions are added to the haemo-
lymph of the horseshoe crab. A coagulation reaction
takes place for as long as the endotoxin concentration
is sufficient. Due to the 1:1 dilution methodology used
in the assay, the true endotoxin concentration lies
between 50% and 200% of the reported concentration.
This is a plausible explanation for the highly variable
in vitro potency results of the #1188844 lot described in
the present study. An alternative endotoxin measure-
ment method is the endotoxin activity assay (EAA).
This assay involves chemiluminescent measurement
on the oxidative burst reaction of activated neutrophils
to complement-coated LPS-IgM immune complexes.18
As such, this assay does not measure endotoxin content
directly. The use of endogenous neutrophils in the
assay represents a potential limitation, as there may
exist large inter-individual differences in neutrophils,
especially under pathological conditions, which might
not be fully corrected by the use of positive and nega-
tive controls in the assay.18 Furthermore, the EAA
assay can only be performed in real time using whole
blood, not on stored material, and the results are semi-
quantitative (i.e. the assay reports low, intermediate, or
high endotoxin levels). Recently, a reversed HPLC/MS
method to detect endotoxin in biological samples was
developed, which is based on quantifying 3HM, the
most abundant hydroxylated fatty acid of the lipid A
moiety.14 Plasma endotoxin levels measured using this
new method were shown to correlate with disease
severity in patients suffering from systemic inflamma-
tory response syndrome.19 This method appears to be
promising, but requires additional validation.
Our results show that there exists considerable var-
iation in inflammation parameters between individual
studies, which for example can be attributed to differ-
ences in diet, genetic background, and previous ill-
nesses. Especially the variation in symptoms was
substantial, but it has to be emphasized that symptom
scores are notoriously subjective.20 Endotoxin experi-
ments in our department were carried out with one,
two, or three subjects simultaneously in the same
room. Therefore, it is possible that symptoms reported
are affected by the presence of symptoms in the
other subjects.
Lot #1188844 was large and was used in over 17
studies over a period of 10 yr in our centre alone.
New lots from the new GMP-grade batch are produced
in smaller quantities. Herein, we report results obtained
using the new lots #94332B1 and #94332B4, and these
lots already have several successors. Although lot
#94332B1 was more potent than #1188844 using
the bolus administration model, the other new lot
(#94332B4) showed to be less potent than lot
#1188844 in the continuous infusion model. These find-
ings suggest that there are potency differences between
these two new lots, despite the fact that they are derived
from the same bulk material. However, because we
used different modes of endotoxin administration and
did not compare these two new lots head-to-head, no
definite conclusions can be drawn pertaining to this
issue. For now, it is only safe to conclude that directly
comparing responses induced by different lots of endo-
toxin is not recommended, and that a control group
(e.g. a group that only receives endotoxin) should
always be included in intervention studies using the
experimental human endotoxemia model.
This work has several limitations. First, subjects
who received a bolus of lot #94332B1 had a 14%
higher body mass, but similar length compared with
subjects that received a bolus of the #1188844 lot.
Therefore, they received 14% more endotoxin as it is
dosed per kg body mass, which theoretically could par-
tially explain the increased cytokine production and
symptoms. However, we have previously shown that
BMI does not correlate with the endotoxin-induced
increase in plasma cytokine levels, nor with the increase
in body temperature.21 Furthermore, taking into
account that previous work did not reveal a propor-
tional increase in the cytokine response with higher
dosages of endotoxin,6 the 200–300% increase in cyto-
kine levels observed in the #94332B1 group is unlikely
to be explained by the 14% higher endotoxin dose.
Another drawback is that we only present a limited
set of inflammatory parameters for the in vivo potency
analysis over time. It would have been valuable to
include cytokine responses as well. Unfortunately,
this is not possible, as original cytokine data were
obtained using various assays which are not sufficiently
comparable due to inter-assay variability, and plasma
samples are no longer available for batchwise reanaly-
sis. Furthermore, cytokines show substantial degrada-
tion after 5 yr, even when stored at –80C.22 A final
limitation is that the LAL tests were performed by sev-
eral commercial parties, which adds an extra source
of variation.
In conclusion, similar to the previous lots, administra-
tion of lots derived from the novelGMP-grade endotoxin
batch elicit a transient, controlled, and safe systemic
inflammatory response in humans in vivo. However,
newer lots of endotoxin are neither necessarily equipotent
to previous lots, nor to other new lots. Although we
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found no evidence for loss of potency of the #1188844 lot
over time, there is considerable inter-study variability in
inflammatory parameters, despite using the same lot of
endotoxin and experimental protocol. As such, we pro-
pose that for interventional studies with, for example,
immunomodulatory compounds, direct comparison of
cytokine responses or clinical parameters of systemic
inflammation is only valid using a control group within
the same study, using the same lot of endotoxin.
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